|
|
Article: A major breakthrough and global first in Group B Streptococcus detection in pregnant women - FDA authorizes IDI-Strep B(TM) test for commercialization on the American market.
- Article from:
- PR Newswire
- Article date:
- November 19, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
QUEBEC CITY -- In a press release issued yesterday, the U.S. Food and Drug Administration (FDA) announced that the IDI-Strep B(TM) test has been authorized for commercialization on the American market. Designed and developed by Infectio Diagnostic Inc. (IDI) of Quebec City, Canada, this test enables health professionals to detect Group B Streptococcus in pregnant women in under an hour at the time of delivery. IDI-Strep B(TM) is also authorized for use at all other phases of pregnancy, primarily between the 35th and 37th weeks. "This is important news for the diagnostic of infectious diseases. Our IDI-Strep B(TM) assay is the first clinical diagnostic test cleared by the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Marketing alliance formed. (News).(IDI Inc., IBC ...
Industrial Distribution;
December 1, 2001 ;
700+ words
... ... Ontario. Founded in 1981, IDI has 95 members with 114 industrial ... program Industrial Supply Plus[TM] but are introducing a new program. "IDI is strong in industrial supply ... rolling out Bearing Supply Plus[TM]," he said. "We have developed ...
|
|